Overdrive
Combines tadalafil with bremelanotide, a melanocortin-receptor agonist sometimes used for libido support, alongside pycnogenol.
No commitment · Cancel anytime · Physician evaluation required
Overview
Combines tadalafil with bremelanotide, a melanocortin-receptor agonist sometimes used for libido support, alongside pycnogenol.
This formulation is compounded by a licensed 503A pharmacy pursuant to an individual prescription following a physician evaluation.
How It's Used
Your prescribing physician will determine the appropriate starting dose and tier based on your health history, current medications, and treatment goals. Follow your physician's specific instructions — do not adjust dose or frequency on your own.
Safety & Considerations
PDE5 inhibitors (the class that includes sildenafil, tadalafil, and vardenafil) must never be combined with nitrate medications (including nitroglycerin) or recreational “poppers,” as this combination can cause a sudden, severe, and potentially fatal drop in blood pressure. Patients taking alpha-blockers for blood pressure or prostate symptoms should disclose this to their prescriber, as the combination can also cause significant blood pressure drops. Seek immediate medical attention for an erection lasting longer than 4 hours (priapism), or for sudden vision or hearing loss/changes. Use with caution in patients with cardiovascular disease — a physician must assess whether sexual activity is safe for the patient's heart health before prescribing.
This formulation contains bremelanotide, which is FDA-approved (as Vyleesi) only for hypoactive sexual desire disorder in premenopausal women — its use here is off-label, including its use in men. It can cause nausea, flushing, headache, and a temporary increase in blood pressure. It is not recommended for patients with uncontrolled hypertension or known cardiovascular disease without physician clearance.
Compounded Medication Disclosure
These statements have not been evaluated by the Food and Drug Administration. This product is not FDA-approved, has not been evaluated by the FDA for safety, effectiveness, or quality, and is not represented as a generic or equivalent version of any FDA-approved drug.
References
This is a compounded, multi-ingredient formulation and, as such, has not itself been studied in dedicated clinical trials. The references below are the FDA prescribing information (or, where noted, peer-reviewed literature) for each individual active ingredient in this formulation. Ask your physician for further ingredient-specific information.
- Tadalafil Tablets — FDA Prescribing Information
DailyMed, National Library of Medicine - VYLEESI (bremelanotide) — FDA Prescribing Information (HSDD in premenopausal women indication; use in this product is off-label)
U.S. FDA